Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 22

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 22
---
 Agreement and the transactions contemplated hereby, including the Contemplated                                                                                                                                  
 Transactions and the Distribution (provided that this clause (H) shall not apply to any representation or warranty (or any Party’s obligation to consummate the Agreement relating to such representation or warranty) to the extent the 
 purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Agreement and the other transactions contemplated hereby);              |

| (I) | any matter expressly consented to in writing by the Purchaser after the date hereof or any action or inaction 
 expressly required by this Agreement; or                                                                      |

| (J) | any Permitted Disposition; |

| provided, however, that where the change or effect referred to in (A) through (E) primarily relates only                                                                                                                                                  
 to (or has the effect of primarily relating only to) the Company and its Subsidiary or disproportionately affects the Company and its Subsidiary, taken as a whole, compared to other entities of similar size operating in the same jurisdictions in the 
 industries and businesses in which the Company and its Subsidiary operate, such change or effect may be taken into account in determining whether a Material Adverse Change has occurred, but only to the extent of such disproportionate impact;         
 provided, further, that references in certain sections of this Agreement to dollar amounts are not intended to be, and shall not be deemed to be, illustrative or interpretative for purposes of determining whether a Material Adverse Change has        
 occurred;                                                                                                                                                                                                                                                 |

- 9 -

| (bbbb) | “Material Contract” means, collectively, the material Contracts of the Company and its                                                                                                                                                                  
 Subsidiary set out in Schedule 19 to the Disclosure Letter, and any and all other Contracts, commitments, agreements (written or oral), instruments, leases or other documents or arrangements to which the Company or its Subsidiary are a party or to 
 which their properties or assets are otherwise bound, and which are material to the Company and its Subsidiary, taken as a whole, other than, in each case, any Employee Plan;                                                                          |

| (cccc) | “material fact” has the meaning ascribed thereto in the Securities Act 
 (Québec);                                                              |

| (dddd) | “Meeting” means the special meeting of Shareholders, including any adjournment or                                                                                                       
 postponement of such special meeting in accordance with the terms of this Agreement, to be